ALCLS Share Price

Open 29.61 Change Price %
High 30.00 1 Day -2.73 -9.22
Low 26.72 1 Week 0.00 0.00
Close 26.88 1 Month 1.93 7.74
Volume 325141 1 Year 9.42 53.95
52 Week High 30.00
52 Week Low 15.55
ALCLS Important Levels
Resistance 2 29.92
Resistance 1 28.67
Pivot 27.87
Support 1 25.09
Support 2 23.84
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLFCI 0.31 34.78%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
ALFRE 1.81 25.69%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
More..
EPA France Top Losers Stocks
MLROU 6.37 -34.19%
MLLEA 0.61 -23.75%
ALAUP 0.20 -13.04%
OXI 0.08 -11.11%
OXI 0.08 -11.11%
MLFXO 3.79 -9.98%
TONN 1.20 -9.77%
ALCLS 26.88 -9.22%
RUSAL 10.00 -9.09%
ALEUP 0.20 -9.09%
More..

Cellectis SA (EPA: ALCLS)

ALCLS Technical Analysis 4
As on 1st Nov 2017 ALCLS Share Price closed @ 26.88 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 21.12 & Buy for SHORT-TERM with Stoploss of 23.74 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALCLS Target for November
1st Target up-side 33.35
2nd Target up-side 36.07
3rd Target up-side 38.79
1st Target down-side 25.59
2nd Target down-side 22.87
3rd Target down-side 20.15
ALCLS Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cellectis.com
ALCLS Address
ALCLS
8 rue de la Croix Jarry
Paris, 75013
France
Phone: 33 1 81 69 16 00
ALCLS Latest News
Interactive Technical Analysis Chart Cellectis SA ( ALCLS EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cellectis SA
ALCLS Business Profile
Cellectis, together with its subsidiaries, operates as a genome engineering company in France and internationally. The company designs and markets meganucleases and TALENs, which are tools that enable targeted modifications to DNA in the research, biomanufacturing, agro biotechnology, and therapeutic sectors; and develops and markets genome customization products used to create stable and isogenic cell lines with various characteristics and performances for use in the drug development, gene function studies, and protein production sectors. It also develops nucleases for various therapeutic applications, including correction of a genetic defect in the patient’s genome; destruction of viral genomes; or inactivation of genes to create cells with modified characteristics in the fields of cancer, viral infections, and genetic diseases. In addition, the company focuses on plant genome modification using nucleases that recognize specific DNA sequences to develop species with traits of value; and development of stem cell technology for controlling stem cell production and differentiation. It has strategic partnership agreement with Les Laboratoires Servier to develop and commercialize product candidates targeting leukemia and solid tumors. Cellectis was founded in 1999 and is based in Paris, France.